JP2021502116A5 - - Google Patents

Info

Publication number

JP2021502116A5

JP2021502116A5 JP2020544130A JP2020544130A JP2021502116A5 JP 2021502116 A5 JP2021502116 A5 JP 2021502116A5 JP 2020544130 A JP2020544130 A JP 2020544130A JP 2020544130 A JP2020544130 A JP 2020544130A JP 2021502116 A5 JP2021502116 A5 JP 2021502116A5

Authority

JP

Japan

Prior art keywords

seq

amino acid

acid sequence

cdr1

cdr2

Prior art date

2018-11-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims description 1016
• 239000000427 antigen Substances 0.000 claims description 116
• 102000036639 antigens Human genes 0.000 claims description 116
• 108091007433 antigens Proteins 0.000 claims description 116
• 102000039446 nucleic acids Human genes 0.000 claims description 35
• 108020004707 nucleic acids Proteins 0.000 claims description 35
• 150000007523 nucleic acids Chemical class 0.000 claims description 35
• 239000013604 expression vector Substances 0.000 claims description 31
• 210000004027 cell Anatomy 0.000 claims description 28
• 239000000203 mixture Substances 0.000 claims description 21
• 238000000034 method Methods 0.000 claims description 19
• 206010028980 Neoplasm Diseases 0.000 claims description 8
• 201000011510 cancer Diseases 0.000 claims description 8
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
• 201000009030 Carcinoma Diseases 0.000 claims description 5
• 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims description 5
• 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims description 5
• 206010009944 Colon cancer Diseases 0.000 claims description 4
• 208000035473 Communicable disease Diseases 0.000 claims description 4
• 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 4
• 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 4
• 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
• 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
• 208000029742 colonic neoplasm Diseases 0.000 claims description 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
• 208000035475 disorder Diseases 0.000 claims description 4
• 230000004064 dysfunction Effects 0.000 claims description 4
• 210000002865 immune cell Anatomy 0.000 claims description 4
• 208000015181 infectious disease Diseases 0.000 claims description 4
• 201000001441 melanoma Diseases 0.000 claims description 4
• 238000000338 in vitro Methods 0.000 claims description 3
• 238000004519 manufacturing process Methods 0.000 claims description 3
• 230000002265 prevention Effects 0.000 claims description 3
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
• 206010005003 Bladder cancer Diseases 0.000 claims description 2
• 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
• 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
• 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
• 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
• 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
• 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
• 102000017578 LAG3 Human genes 0.000 claims description 2
• 101150030213 Lag3 gene Proteins 0.000 claims description 2
• 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
• 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
• 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
• 206010033128 Ovarian cancer Diseases 0.000 claims description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
• 206010060862 Prostate cancer Diseases 0.000 claims description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
• 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
• 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
• 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
• 201000010881 cervical cancer Diseases 0.000 claims description 2
• 239000003795 chemical substances by application Substances 0.000 claims description 2
• 210000001072 colon Anatomy 0.000 claims description 2
• 238000012258 culturing Methods 0.000 claims description 2
• IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
• 206010017758 gastric cancer Diseases 0.000 claims description 2
• 201000010536 head and neck cancer Diseases 0.000 claims description 2
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
• 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
• 201000005202 lung cancer Diseases 0.000 claims description 2
• 208000020816 lung neoplasm Diseases 0.000 claims description 2
• 230000001404 mediated effect Effects 0.000 claims description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
• 206010038038 rectal cancer Diseases 0.000 claims description 2
• 201000001275 rectum cancer Diseases 0.000 claims description 2
• 230000019491 signal transduction Effects 0.000 claims description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
• 201000011549 stomach cancer Diseases 0.000 claims description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
• 210000001635 urinary tract Anatomy 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 description 12
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 7
• 230000004083 survival effect Effects 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
• 206010071541 Metastatic lymphoma Diseases 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1